ArticleScientific reports2026
Sensitive and quantitative biosensing technique based on NV centres-doped nanodiamonds applied to lateral flow assays.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This paper presents the development of an innovative biomarker detection technology based on NV centres. In order to provide initial proofs of concept for the technique, we applied this detection technique to Lateral Flow Assays (LFA) through the use of NV-doped functionalised nanodiamonds (ND) as LFA labels. The remarkable properties of NV centres in diamond enable a sensitive and quantitative detection of biomarkers with an LFA label that is robust to external perturbation, easy to handle and functionalisable for a wide range of targets. The aim of NV-based LFA is to combine the advantages of the most widely used LFA - i.e. high speed, simplicity and low cost - with quantitative and highly sensitive measurements in a large detection range, from pg/mL limit of detection to mg/mL. Such detection could be of great interest in a variety of applications where simple but sensitive detection is required, for e.g. biomedical, agri-food or ecotoxicology diagnostics. NV-doped nanodiamonds have already shown promise as alternative labels in LFA, yet lack quantitative comparison with conventional markers. This study addresses this gap by validating an NV-based LFA setup for cancer antigen detection and providing a first experimental comparison with standard LFA labels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.